<DOC>
	<DOCNO>NCT01462162</DOCNO>
	<brief_summary>This prospective observational study investigate effect tocilizumab fatigue participant moderate severe rheumatoid arthritis inadequate response disease-modifying antirheumatic drug anti-tumour necrosis factor ( anti-TNF ) drug . Data collect participant 6 month .</brief_summary>
	<brief_title>A Prospective Observational Study Tocilizumab ( RoActemra/Actemra ) Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants moderate severe RA consider propose rheumatologist start treatment Tocilizumab accord his/her clinical judgment condition approve Summary Product Characteristics ( SPC ) . Participants previously currently treat RoActemra/Actemra clinical trial Absolute neutrophil count less equal ( &lt; /= ) 2x10^9 per liter ( /L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>